Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBT: 2013-2024

Historic EBT for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$413.6 million.

  • ImmunityBio's EBT rose 21.51% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 40.69%. This contributed to the annual value of -$413.6 million for FY2024, which is 29.16% up from last year.
  • ImmunityBio's EBT amounted to -$413.6 million in FY2024, which was up 29.16% from -$583.9 million recorded in FY2023.
  • ImmunityBio's 5-year EBT high stood at -$226.0 million for FY2020, and its period low was -$583.9 million during FY2023.
  • For the 3-year period, ImmunityBio's EBT averaged around -$471.6 million, with its median value being -$417.3 million (2022).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 54.77% in 2021, then increased by 29.16% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's EBT stood at -$226.0 million in 2020, then slumped by 54.77% to -$349.8 million in 2021, then decreased by 19.28% to -$417.3 million in 2022, then slumped by 39.93% to -$583.9 million in 2023, then increased by 29.16% to -$413.6 million in 2024.